LYT-200 Gains FDA Fast Track Status in Acute Myeloid Leukemia
Jan 14, 2025 · LYT-200 now has gained fast track designation from the FDA in acute myeloid leukemia in addition to its prior designation for recurrent or metastatic head and neck …
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal …
Dec 9, 2024 · LYT-200 is currently being evaluated both as a monotherapy and in combination with the standard-of-care venetoclax and hypomethylating agents (HMA) for patients whose …
PureTech announces receipt of FDA Fast Track Designation for LYT-200 …
Jan 10, 2025 · PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class anti-galectin-9 monoclonal …
FDA Grants Fast Track Designation to LYT-200 for AML - Docwire News
Jan 10, 2025 · LYT-200 has received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML), according to a press …
PureTech Says FDA Grants Fast Track Designation For LYT-200 In …
Jan 9, 2025 · (RTTNews) - Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted Fast Track …
PureTech Receives FDA Fast Track Designation for LYT-200 in …
Jan 9, 2025 · LYT-200 exerts its therapeutic effects in AML by killing cancer cells directly via apoptosis and DNA damage as well as reactivating central anti-cancer effectors of the immune …
FDA gives LYT-200 fast track status as potential AML treatment
Jan 13, 2025 · The U.S. Food and Drug Administration (FDA) has granted fast track designation to Puretech Health ’s LYT-200, an investigative treatment for acute myeloid leukemia (AML), a …
PureTech Presents Lyt-200 Data for Relapsed/Refractory AML/MDS
PureTech Health presented positive Phase 1b trial data for LYT-200, a novel anti-galectin-9 monoclonal antibody, in patients with relapsed or refractory acute myeloid leukemia (AML) and …
FDA Grants Fast Track Designation to LYT-200 in Recurrent
Apr 11, 2024 · The FDA has granted fast track designation to the IgG4 monoclonal antibody LYT-200 in combination with a PD-1 inhibitor for the treatment of patients with recurrent or …
PureTech Health presents data from dose escalation phase of LYT-200 ...
When administered in combination with venetoclax/HMA, results demonstrate that LYT-200 may enhance the efficacy of standard-of-care therapies, even in relapsed or refractory patients. In …
- Some results have been removed